Regulation of GLP-1 on PERK-eIF2 α-ATF4 Pathway in Non-alcoholic Fatty Pancreas Disease
Description
Non-alcoholic fatty pancreas disease (NAFPD) is a newly recognized condition, which is poorly investigated until today as compared to nonalcoholic fatty liver disease (NAFLD) despite the growing attention of NAFPD. It is characterized by pancreatic fat accumulation and subsequent development of pancreatic and metabolic complications. Association of NAFPD have been described with type 2 diabetes mellitus, Metabolic syndrome，acute and chronic pancreatitis and even pancreatic carcinoma. Considering the clinical significance of NAFPD, it is urgent to find a treatment for NAFPD. Researches have revealed that the GLP-1 could significantly improve the NAFLD by inhibiting the endoplasmic reticulum (ER)stress. Given that the liver and pancreas have similar embryological origins and ectopic fat deposition, it is also plausible, as recommended for NAFLD, that GLP-1 could improve NAFPD by suppressing ER stress. Thus, the aim of our research is to prove hypotheses that ER stress may take part in the pathogenesis of NAFPD and the inhibition of GLP-1 on ER stress may improve NAFPD. The Liraglutide Could impress the ER stress in NAFPD mice.